Arovella Therapeutics Ltd (fra:E4NA) Share Price

Company Profile

Business description
Arovella Therapeutics Ltd is engaged in the development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer. Its invariant Natural Killer T (iNKT) cell therapy platform is being developed as a next-generation, allogeneic off-the-shelf cell therapy platform with potential applications across blood cancers, solid tumours and selected autoimmune diseases. Its product, ALA-101, is a CD19-directed CAR-iNKT cell therapy for relapsed or refractory CD19- positive blood cancers. Arovella is expanding the platform into solid tumours through ALA-105, its CLDN18.2-targeting CAR-iNKT program for gastric and pancreatic cancers, and through incorporation of IL-12-TM armouring technology designed to enhance CARiNKT cell activity and durability.
Contact
84 Hotham Street
Corporate One
PrestonVIC3072
AUS
T: +61 398245254
https://www.arovella.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
44

Recommended

Fear outweighs fundamentals as ASX share reaffirms outlook.

Nathan Zaia | 29 October 2026

We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.

Eric Compton, CFA | 29 October 2026

We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.

Malik Ahmed Khan, CFA | 29 October 2026

Index	Last price	Change	% Change
All Ordinaries	9,025.40	12.80	0.14%
CAC 40	7,970.00	83.04	1.05%
DAX 40	26,039.68	335.66	1.31%
Dow JONES (US)	52,342.56	132.54	-0.25%
FTSE 100	10,722.07	27.57	0.26%
HKSE	23,345.90	387.25	1.69%
NASDAQ	26,184.72	365.13	-1.38%
Nikkei 225	63,290.11	1,369.36	-2.12%
NZX 50 Index	13,797.00	86.83	0.63%
S&P 500	7,720.39	23.59	-0.30%
S&P/ASX 200	8,908.10	16.30	0.18%
SSE Composite Index	3,612.48	38.96	-1.07%